TNFRSF11A and neoplasm: It binds to RANKL with high affinity and specificity and inhibits the binding of RANKL to osteoclast precursors and osteoclast surface RANK, thus inhibiting osteoclast differentiation and activity, and disrupting the “vicious cycle” in tumor bone metastasis.